Pharmaceuticals in Spain
Pharmaceuticals in Spain
SUMMARY
Pharmaceuticals in Spain industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
SUMMARY
Pharmaceuticals in Spain industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
- The Spanish pharmaceuticals market had total revenues of $24,800.0m in 2019, representing a compound annual growth rate (CAGR) of 4.5% between 2015 and 2019.
- Like other European countries, the Spanish pharmaceuticals market is being pushed towards a value focus with respect to its medicines, with healthcare systems pushed to ensure access to innovative products in a sustainable way.
- As of 2018, 19.29% of the Spanish population was aged 65 or over. As a result, the market has been supported to some degree by the country’s aging population and an increase in age-associated disease.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Spain
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Spain
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Spain pharmaceuticals market with five year forecasts
- What was the size of the Spain pharmaceuticals market by value in 2019?
- What will be the size of the Spain pharmaceuticals market in 2024?
- What factors are affecting the strength of competition in the Spain pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitiors in Spain's pharmaceuticals market?
1 EXECUTIVE SUMMARY
1.1. Market value
1.2. Market value forecast
1.3. Geography segmentation
1.4. Market share
1.5. Market rivalry
1.6. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Market share
7.2. Who are the leading players?
7.3. What are the strengths/weaknesses of leading players?
7.4. What strategies do leading players follow?
7.5. What has been the rationale behind recent collaborations?
7.6. Are there any threats towards leading players?
8 COMPANY PROFILES
8.1. Almirall S.A.
8.2. GlaxoSmithKline Plc
8.3. AstraZeneca AB
9 MACROECONOMIC INDICATORS
9.1. Country data
10 APPENDIX
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
1.1. Market value
1.2. Market value forecast
1.3. Geography segmentation
1.4. Market share
1.5. Market rivalry
1.6. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Market share
7.2. Who are the leading players?
7.3. What are the strengths/weaknesses of leading players?
7.4. What strategies do leading players follow?
7.5. What has been the rationale behind recent collaborations?
7.6. Are there any threats towards leading players?
8 COMPANY PROFILES
8.1. Almirall S.A.
8.2. GlaxoSmithKline Plc
8.3. AstraZeneca AB
9 MACROECONOMIC INDICATORS
9.1. Country data
10 APPENDIX
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
LIST OF TABLES
Table 1: Spain pharmaceuticals market value: $ billion, 2015-19
Table 2: Spain pharmaceuticals market geography segmentation: $ billion, 2019
Table 3: Spain pharmaceuticals market value forecast: $ billion, 2019-24
Table 4: Spain pharmaceuticals market share: % share, by value, 2019
Table 5: Almirall S.A.: key facts
Table 6: Almirall S.A.: Annual Financial Ratios
Table 7: Almirall S.A.: Key Employees
Table 8: GlaxoSmithKline Plc: key facts
Table 9: GlaxoSmithKline Plc: Annual Financial Ratios
Table 10: GlaxoSmithKline Plc: Annual Financial Ratios (Continued)
Table 11: GlaxoSmithKline Plc: Key Employees
Table 12: GlaxoSmithKline Plc: Key Employees Continued
Table 13: AstraZeneca AB: key facts
Table 14: AstraZeneca AB: Key Employees
Table 15: Spain size of population (million), 2015-19
Table 16: Spain gdp (constant 2005 prices, $ billion), 2015-19
Table 17: Spain gdp (current prices, $ billion), 2015-19
Table 18: Spain inflation, 2015-19
Table 19: Spain consumer price index (absolute), 2015-19
Table 20: Spain exchange rate, 2015-19
Table 1: Spain pharmaceuticals market value: $ billion, 2015-19
Table 2: Spain pharmaceuticals market geography segmentation: $ billion, 2019
Table 3: Spain pharmaceuticals market value forecast: $ billion, 2019-24
Table 4: Spain pharmaceuticals market share: % share, by value, 2019
Table 5: Almirall S.A.: key facts
Table 6: Almirall S.A.: Annual Financial Ratios
Table 7: Almirall S.A.: Key Employees
Table 8: GlaxoSmithKline Plc: key facts
Table 9: GlaxoSmithKline Plc: Annual Financial Ratios
Table 10: GlaxoSmithKline Plc: Annual Financial Ratios (Continued)
Table 11: GlaxoSmithKline Plc: Key Employees
Table 12: GlaxoSmithKline Plc: Key Employees Continued
Table 13: AstraZeneca AB: key facts
Table 14: AstraZeneca AB: Key Employees
Table 15: Spain size of population (million), 2015-19
Table 16: Spain gdp (constant 2005 prices, $ billion), 2015-19
Table 17: Spain gdp (current prices, $ billion), 2015-19
Table 18: Spain inflation, 2015-19
Table 19: Spain consumer price index (absolute), 2015-19
Table 20: Spain exchange rate, 2015-19
LIST OF FIGURES
Figure 1: Spain pharmaceuticals market value: $ billion, 2015-19
Figure 2: Spain pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 3: Spain pharmaceuticals market value forecast: $ billion, 2019-24
Figure 4: Forces driving competition in the pharmaceuticals market in Spain, 2019
Figure 5: Drivers of buyer power in the pharmaceuticals market in Spain, 2019
Figure 6: Drivers of supplier power in the pharmaceuticals market in Spain, 2019
Figure 7: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Spain, 2019
Figure 8: Factors influencing the threat of substitutes in the pharmaceuticals market in Spain, 2019
Figure 9: Drivers of degree of rivalry in the pharmaceuticals market in Spain, 2019
Figure 10: Spain pharmaceuticals market share: % share, by value, 2019
Figure 1: Spain pharmaceuticals market value: $ billion, 2015-19
Figure 2: Spain pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 3: Spain pharmaceuticals market value forecast: $ billion, 2019-24
Figure 4: Forces driving competition in the pharmaceuticals market in Spain, 2019
Figure 5: Drivers of buyer power in the pharmaceuticals market in Spain, 2019
Figure 6: Drivers of supplier power in the pharmaceuticals market in Spain, 2019
Figure 7: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Spain, 2019
Figure 8: Factors influencing the threat of substitutes in the pharmaceuticals market in Spain, 2019
Figure 9: Drivers of degree of rivalry in the pharmaceuticals market in Spain, 2019
Figure 10: Spain pharmaceuticals market share: % share, by value, 2019